Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxart, Inc. (VXRT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain the contents of each document in clear language. As a clinical-stage biotechnology company developing oral recombinant pill vaccines, Vaxart uses its filings to report on clinical progress, collaborations, listing status and material agreements that shape its vaccine platform and financial position.
Through Vaxart’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, investors can review detailed discussions of its oral vaccine programs for coronavirus, norovirus, influenza and HPV, as well as information on research and development spending, government contract revenue and risk factors. Current reports on Form 8‑K highlight specific events, such as the exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart’s oral COVID-19 vaccine candidate, updates on the BARDA-funded Project NextGen Phase 2b trial, lease terminations related to cost reduction efforts, and governance and listing developments.
For trading status, Vaxart’s 8‑K filings and the Form 25 filed by Nasdaq Stock Market LLC document the suspension and removal of the company’s common stock from Nasdaq and its quotation on the OTCQX Best Market under the symbol VXRT. These filings provide the official record of Vaxart’s transition from a national exchange to OTCQX and the conditions that led to delisting.
On this page, users can also monitor any registration statements, prospectus supplements and other capital markets filings that Vaxart uses to raise funds or register securities, as well as any future proxy materials related to corporate actions. Stock Titan’s AI tools summarize long forms such as 10‑K and 10‑Q, highlight key sections on clinical programs, government contracts and collaboration terms, and surface important items from 8‑Ks so that readers can quickly understand how each filing may relate to Vaxart’s oral vaccine development and trading status.
Vaxart, Inc. reported third‑quarter results highlighting a sharp rise in government contract revenue and a strengthened liquidity outlook. Revenue reached $72.4 million for the quarter, driven by HHS BARDA contracts tied to the ATI‑RRPV program, while operating expenses were $80.2 million, resulting in an operating loss of $7.8 million and a net loss of $8.1 million (basic and diluted loss per share of $0.04).
Cash, cash equivalents and short‑term investments totaled $28.8 million as of September 30, 2025. The balance sheet reflects $42.7 million in accounts receivable and $43.2 million in unbilled receivables from government contracts, alongside $64.8 million in deferred government revenue. Vaxart recognized $71.8 million of cost‑plus‑fixed‑fee revenue in Q3 under the 2024 ATI‑RRPV Contract.
After quarter‑end, Vaxart entered an exclusive license and collaboration with Dynavax, including a $25.0 million upfront fee and a $5.0 million equity purchase at $0.45 per share, providing approximately $30.0 million in total proceeds. Management reports these actions extend cash runway into the second quarter of 2027. Shares outstanding were 240,069,844 as of November 6, 2025.
Vaxart, Inc. (VXRT) furnished an 8-K to announce it issued a press release with a business update and financial results for the quarter ended September 30, 2025. The company attached the release as Exhibit 99.1 and stated the information is being furnished, not filed, under the Exchange Act and Securities Act provisions.
Vaxart also noted its common stock trades exclusively on the OTCQX Best Market under the symbol VXRT. No specific financial figures are included in this report; details are contained in the press release referenced as Exhibit 99.1.
Vaxart, Inc. is offering and selling 11,111,111 shares of common stock at $0.45 per share in a privately negotiated transaction with Dynavax Technologies Corporation.
The company estimates net proceeds of approximately $5 million, to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. No underwriters or placement agents are involved. Delivery of shares is expected on or about November 6, 2025. Shares outstanding were 228,957,259 as of September 30, 2025, and are expected to be 240,069,844 immediately after the offering. Vaxart’s stock trades on the OTCQX under VXRT; the last reported price on November 3, 2025 was $0.33 per share.
Vaxart (VXRT) signed an exclusive, worldwide license and collaboration with Dynavax for its investigational oral coronavirus vaccines, including its oral COVID‑19 candidate. Vaxart will complete its ongoing Phase 2b trial and an end‑of‑Phase 2 FDA meeting; after that, Dynavax may elect to assume further development.
Dynavax will pay $25 million upfront and purchase 11,111,111 Vaxart shares at $0.45 per share (about $5 million) under Vaxart’s shelf registration, with closing expected on or about November 6, 2025. If Dynavax elects to take over development, it will pay an additional $50 million.
Vaxart may receive up to $195 million in regulatory milestones, up to $425 million in net sales milestones, and tiered royalties in the low‑to‑mid teens on net sales for licensed indications. Vaxart retains its platform rights for all non‑coronavirus indications. If Dynavax does not elect to continue, the agreement will terminate.
On
Vaxart, Inc. reports that Nasdaq has decided to delist its securities after the company failed to meet conditions previously set by a Nasdaq Hearings Panel. Those conditions required shareholder approval of a reverse stock split by September 5, 2025, completion of the reverse split by October 6, 2025, and proof that the company met Nasdaq’s minimum bid price requirement. Vaxart withdrew its reverse stock split proposal on September 18, 2025, which left these conditions unmet.
Nasdaq’s Office of the General Counsel sent a letter on September 19, 2025 stating that Vaxart’s securities will be delisted. Trading of Vaxart’s common stock on Nasdaq has already been suspended since the open of trading on July 8, 2025. The company’s common stock is currently quoted on the OTCQX® Best Market under the symbol VXRT, meaning its shares continue to trade but no longer on a national securities exchange.
Vaxart, Inc. informed investors that a previously adjourned special meeting of stockholders, originally convened on
Vaxart, Inc. faces an organized shareholder opposition: a group calling itself the Concerned Vaxart Stockholders issued an exempt solicitation press release dated
The group notes the reverse split was overwhelmingly rejected at the